These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 38894541)

  • 1. Clinical perspectives: Treating spinal muscular atrophy.
    McPheron MA; Felker MV
    Mol Ther; 2024 Aug; 32(8):2489-2504. PubMed ID: 38894541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
    Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
    Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies.
    Motta-Santos A; Noronha K; Reis C; Freitas D; Carvalho L; Andrade M
    Value Health Reg Issues; 2024 Jul; 42():100985. PubMed ID: 38669792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 5. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians.
    Ramdas S; Oskoui M; Servais L
    Drugs; 2024 Jul; 84(7):747-762. PubMed ID: 38878146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies.
    Giess D; Erdos J; Wild C
    Eur J Paediatr Neurol; 2024 Jul; 51():84-92. PubMed ID: 38905882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e1-e2. PubMed ID: 34544108
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy.
    Waldrop MA
    Neurotherapeutics; 2024 Jul; 21(4):e00437. PubMed ID: 39241317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adult Spinal Muscular Atrophy].
    Walter MC; Hiebeler M
    Fortschr Neurol Psychiatr; 2022 Sep; 90(9):421-430. PubMed ID: 36103897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Spinal muscular atrophy].
    Martin P; Horber V; Park J; Kronlage C; Grimm A
    Nervenarzt; 2022 Feb; 93(2):191-200. PubMed ID: 35037967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting disease-modifying medications in 5q spinal muscular atrophy.
    Cartwright MS; Upadhya S
    Muscle Nerve; 2021 Oct; 64(4):404-412. PubMed ID: 34231920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy.
    Powell JC; Meiling JB; Cartwright MS
    Muscle Nerve; 2024 Feb; 69(2):179-184. PubMed ID: 38040488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the Therapy of Spinal Muscular Atrophy.
    Klotz J; Tesi Rocha C; Dunaway Young S; Duong T; Buu M; Sampson J; Day JW
    J Pediatr; 2021 Sep; 236():13-20.e1. PubMed ID: 34197889
    [No Abstract]   [Full Text] [Related]  

  • 19. Spinal Muscular Atrophy.
    Nance JR
    Continuum (Minneap Minn); 2020 Oct; 26(5):1348-1368. PubMed ID: 33003005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-Targeting Therapeutics for Neurological Disease: Lessons Learned from Spinal Muscular Atrophy.
    Ravi B; Chan-Cortés MH; Sumner CJ
    Annu Rev Med; 2021 Jan; 72():1-14. PubMed ID: 33502897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.